Prostate Cancer Screening Saves Lives But Risks Remain

Published: 15 May 2026. The English Chronicle Desk. The English Chronicle Online.

A comprehensive new medical study has delivered a crucial update regarding prostate cancer screening. This extensive research indicates that regular blood tests can successfully save lives across the nation. However, the international team of scientists stresses that the absolute benefit remains relatively small. Many healthy men could still face unnecessary treatment and serious long-term medical complications. This landmark review analysed six major clinical trials involving nearly eight hundred thousand men.

The findings show that the prostate-specific antigen test reduced overall cancer deaths slightly. Specifically, the screening process prevented two deaths for every one thousand men tested. This statistical reality means five hundred men must undergo testing to prevent one death. The true clinical benefits became apparent only as patients were monitored over decades. This long-term trend was particularly clear during a major European randomized screening study. That specific trial carefully followed thousands of male patients for twenty-three years after screening.

Professor Philipp Dahm serves as a senior author for this detailed Cochrane review. He explained that prostate cancer screening definitely reduces mortality over a very extended period. The urologist believes this significant milestone will influence healthcare policymakers around the world. Currently, the United Kingdom lacks a formal national screening programme for prostate cancer. This policy exists largely because the traditional blood test remains somewhat unreliable today. The test routinely detects dangerous tumours but also identifies many completely harmless benign cancers.

These benign cases might never cause any health problems during a man’s lifetime. Consequently, many patients undergo radiotherapy, invasive surgery, or intensive hormone therapy without need. These medical interventions put men at risk of permanent incontinence and impotence. The trials in the review did not systematically measure overall patient quality of life. However, a separate British trial found high rates of urinary and sexual function problems. Between eight and forty-seven percent of treated men reported these severe adverse effects.

Dr Juan Franco works at Heinrich Heine University and led this massive review. He explicitly stated that these results are not a endorsement of universal screening. The researcher emphasized the very real risks of overdiagnosis and subsequent unnecessary treatment. He believes it is vital to have honest discussions and shared decision-making. Prostate cancer remains one of the most common cancers affecting men today. More than sixty-four thousand cases are diagnosed annually across the United Kingdom.

Statistics show that one in eight men will develop this disease eventually. That risk unfortunately rises to one in four for Black men nationwide. Last year, the UK National Screening Committee advised against a widespread national programme. Instead, the expert panel recommended a targeted programme for high-risk genetic mutations. These specific mutations are strongly linked to much more aggressive forms of cancer. Government ministers are currently reviewing this official medical advice for future health policy.

Professor Dahm noted that screening makes sense for men with longer life expectancies. Patients should generally expect to live for at least another ten to fifteen years. If a patient has multiple competing medical conditions, screening is less critical. Most prostate cancers grow very slowly and will not limit a person’s lifespan. The comprehensive review also examined recent technological advances in modern cancer screening methods. These new techniques aim to be much more precise than older testing methods.

Doctors are now testing for additional prostate-related proteins within human blood samples. Medical teams also use advanced scans to image the prostate gland clearly. These modern diagnostic innovations aim to reduce the number of unnecessary tissue biopsies. The researchers stated it is too early to confirm if they save lives. They need more data to prove these methods cause less overall patient harm. David James works at a prominent national charity called Prostate Cancer Research.

He acknowledged that the review successfully showed how screening reduces cancer deaths effectively. However, he also emphasized how much modern diagnosis and treatment have recently evolved. New diagnostic pathways and targeted biopsies are changing the balance of medical care. Active surveillance programs and biomarker tests offer better options for many patients today. Dr Ian Walker works as a director at Cancer Research UK. He explained why a widespread British screening programme does not currently exist.

The review confirms the test saves very few lives per thousand men screened. Meanwhile, about thirty additional men could be diagnosed with the disease needlessly. Many of these diagnosed men would never have been harmed by the cancer. They might still undergo treatment that causes loss of bladder control. These patients also face a high risk of developing permanent erectile dysfunction. Dr Matthew Hobbs represents another leading charity known as Prostate Cancer UK. He stated that the blood test saves lives but not nearly enough.

More research is urgently needed to plug these critical medical evidence gaps. Scientists must find the safest way to screen men for prostate cancer. Future programs must ensure that the clinical benefits clearly outweigh the harms. In the meantime, men at risk must make informed personal choices. Patients need clear access to information before choosing a blood test today. Each individual man must decide what option is best for his future. This research shows that prostate screening is not a simple medical decision. Doctors must be completely honest about the potential harms of this test.

Check our latest news